Ju-Hong Min, MD, PhD1,2, Byoung Joon Kim, MD, PhD1,2, Kwang Kook Kim, MD, PhD3*
1Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea 2Neuroscience Center, Samsung Medical Center, Seoul, Korea 3Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, S
Multiple sclerosis (MS) is a CNS demyelinating disorder, which affects young aged people. In Korea,
the prevalence of MS is very lower than that of western countries. Now, more than 10 disease modifying
therapeutics (DMTs) were discovered; therefore the early diagnosis and treatment optimization
is very important in MS patients. Herein, to understand MS market in Korea, we investigated
the current diagnostic strategy and therapeutic choice of DMTs by Korean MS specialists in
real world practice.
Journal of Multiple Sclerosis 8(2):19-23, 2017
keyword : Multiple sclerosis, Disease modifying therapeutic, Korea
